Gene therapy

Global Contract Cell and Gene Therapy Manufacturing Market Report 2020-2026: CDMO Categorization - Primed for Business Model Disruption

Retrieved on: 
Tuesday, November 24, 2020
Life sciences, Biology, Branches of biology, Biotechnology, Gene therapy, Biopharmaceutical, Therapy

DUBLIN, Nov. 24, 2020 /PRNewswire/ -- The "Global Contract Cell and Gene Therapy Manufacturing Market 2020-2026 - Supply Chain Optimization and Decentralized Manufacturing to Expand the Industry" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 24, 2020 /PRNewswire/ -- The "Global Contract Cell and Gene Therapy Manufacturing Market 2020-2026 - Supply Chain Optimization and Decentralized Manufacturing to Expand the Industry" report has been added to ResearchAndMarkets.com's offering.
  • Additionally, the study explores different cross-sections of the market and discusses market dynamics for autologous and allogeneic solutions for cell and gene therapies and for products being manufactured for clinical trial use and for commercial markets.
  • The variability in market dynamics, manufacturing protocols, and business models across cross-sections is high.
  • The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space.

The South and Central America cell therapy instruments market is expected to reach US$ 462.05 million in 2027 from US$ 1,074.99 million in 2019

Retrieved on: 
Tuesday, November 24, 2020
Branches of biology, Life sciences, Biology, Biotechnology, Stem cells, Cell biology, Gene therapy, Cell therapy, Therapy

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- The South and Central America cell therapy instruments market is expected to reach US$ 462.05 million in 2027 from US$ 1,074.99 million in 2019.

Key Points: 
  • NEW YORK, Nov. 24, 2020 /PRNewswire/ -- The South and Central America cell therapy instruments market is expected to reach US$ 462.05 million in 2027 from US$ 1,074.99 million in 2019.
  • The surge in the number of cell therapy transplantation procedures, growing research and development activities, and rising investments in building production facilities for cell and gene therapy products drive the growth of the South and Central America cell therapy instruments market.
  • On the basis of cell type, the cell therapy instruments market is segmented into animal cells and human cells.
  • Based on enduser, the South and Central America cell therapy instruments market is segmented into life science research companies, research institutes, and other end users.

Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1

Retrieved on: 
Tuesday, November 24, 2020
Oncology, Health, Diabetes, Genetics, Research, Science, Biotechnology, Branches of biology, Biology, Life sciences, Bioethics, Biotechnology, Gene therapy, Molecular biology, Two River, BioMarin Pharmaceutical

Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on December 1, 2020.

Key Points: 
  • Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on December 1, 2020.
  • A live audio webcast and archive of the conference presentation will be available for a period of time using the registration link above.
  • For more information on the Diamond Equity Research Emerging Growth Invitational, please contact your Diamond Equity Research representative.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)

Retrieved on: 
Tuesday, November 24, 2020
Life sciences, Branches of biology, Biology, Biotechnology, European Medicines Agency, European Union, Gene delivery, Orphan drugs, Gene therapy, ABTL0812, Enadenotucirev

The European Medicines Agency (EMA) previously granted Advanced Therapy Medicinal Product classification to MB-107 in April 2020.

Key Points: 
  • The European Medicines Agency (EMA) previously granted Advanced Therapy Medicinal Product classification to MB-107 in April 2020.
  • The U.S. Food and Drug Administration (FDA) also previously granted Rare Pediatric Disease and Orphan Drug Designations to MB-107 and MB-207, as well as Regenerative Medicine Advanced Therapy Designation to MB-107.
  • Orphan Drug Designation in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the European Medicines Agency Committee for Orphan Medicinal Products (EMA COMP).
  • Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, We are very pleased to receive a positive opinion from the EC on Orphan Drug Designation for our lentiviral gene therapy for XSCID.

Taysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of Directors

Retrieved on: 
Tuesday, November 24, 2020
Research, FDA, Genetics, Public relations, Investor relations, Clinical trials, Communications, General Health, Pharmaceutical, Health, Science, Branches of biology, Biology, Life sciences, Molecular biology, Bioethics, Biotechnology, Gene therapy

Reape and Sepp-Lorenzino bring significant gene therapy translational and development expertise to our board, said RA Session II, President, Founder and CEO of Taysha Gene Therapies.

Key Points: 
  • Reape and Sepp-Lorenzino bring significant gene therapy translational and development expertise to our board, said RA Session II, President, Founder and CEO of Taysha Gene Therapies.
  • She also oversaw the development of Sparks pipeline of gene therapies addressing CNS disease, hemophilia, metabolic disorders and inherited retinal dystrophies.
  • Taysha has built a deep pipeline of potentially transformative gene therapies for patients with life-threatening CNS diseases, said Dr. Reape.
  • Joining the Taysha board is a truly exceptional opportunity to contribute to the development of multiple innovative gene therapies, commented Dr. Sepp-Lorenzino.

Orchard Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Retrieved on: 
Tuesday, November 24, 2020
Life sciences, Branches of biology, Health sciences, Drug discovery, Health policy, Medicinal chemistry, Therapy, Gene therapy

BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D. will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Key Points: 
  • BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D. will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference.
  • The fireside chat is available for on-demand viewing under "Events" in the Investors & Media section of the company's website at www.orchard-tx.com and will remain available for approximately 90 days.
  • Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies.
  • The information that Orchard posts on these channels and websites could be deemed to be material information.

REGENXBIO to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, November 23, 2020
Branches of biology, Biology, Applied genetics, Genetics, Gene delivery, Medical genetics, Adeno-associated virus, Parvoviruses, AAV, Gene therapy

A live webcast of the Evercore fireside chat can be accessed in the same section of REGENXBIO's website, and anarchived replay will be available for approximately 30 days following the presentation.

Key Points: 
  • A live webcast of the Evercore fireside chat can be accessed in the same section of REGENXBIO's website, and anarchived replay will be available for approximately 30 days following the presentation.
  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.
  • REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.
  • REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Mekonos raises $4.6M for its gene engineering platform

Retrieved on: 
Monday, November 23, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Emerging technologies, Applied genetics, Molecular biology, Medical genetics, Gene therapy, Synthetic biology

Mekonos will use the new capital to accelerate the SoC platform for its current and new commercial partnerships.

Key Points: 
  • Mekonos will use the new capital to accelerate the SoC platform for its current and new commercial partnerships.
  • The SoC platform, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology.
  • The platform is scalable across all cell types and has shown to be a high yield solution for partners.
  • The platform helps companies increase capacity, accelerate discoveries, and develop new pre-clinical assets in the emerging cell and gene therapy space.

Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference

Retrieved on: 
Monday, November 23, 2020
Branches of biology, Biology, Adverum Biotechnologies, Life sciences, Emerging technologies, Gene delivery, Medical genetics, Molecular biology, Gene therapy

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the companys presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the companys presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
  • Adverums video webcast will be accessible on demand beginning today at 10:00 am ET under Events and Presentations in the Investors section of the company's website.
  • This webcast will be available on the Adverum website for 30 days.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.

Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Retrieved on: 
Monday, November 23, 2020
Branches of biology, Biology, Life sciences, Emerging technologies, Gene delivery, Medical genetics, Molecular biology, Biotechnology, Otology, Gene therapy, Hearing loss

BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1 to 3, 2020.

Key Points: 
  • BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (Akouos) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1 to 3, 2020.
  • The fireside chat will be available for on-demand viewing through the investor relations section of Akouoss website at www.akouos.com , beginning today, Monday, November 23, 2020, and will be available for 14 days following the conference.
  • Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide.
  • Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.